Weight
GLP-3
Metabolic
40
Amino acids
Molecular weight
Peptide
Type
GLP-3 (LY3437943) is a 39-amino-acid synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. By targeting all three receptors, it drives superior weight loss compared to single or dual incretin therapies, with Phase 2 trials showing up to 24.2% body weight reduction at 48 weeks. It is being evaluated in Phase 3 TRIUMPH trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease.
Top researched benefits
Phase II Obesity Trial
Landmark RCT in 338 participants showing dose-dependent weight loss; 12mg dose achieved 24.2% reduction—highest recorded for any obesity medication. NEJM.
Phase II Type 2 Diabetes Study
Trial in 281 participants with type 2 diabetes: 16.9% weight loss and HbA1c reductions up to 2.16%. The Lancet.
GLP-3 Body Targets
The areas of the body that GLP-3 primarily affects.
2
Body Targets
GLP-3
Metabolic
Research targets include lipid metabolism pathways, insulin signaling, and energy homeostasis.
Gut
Research targets include gastrointestinal mucosal integrity, digestive signaling, and the gut-brain axis.
GLP-3 Targeted areas
Overview of GLP-3
GLP-3 activates GLP-1 and GIP receptors to increase insulin secretion, reduce gastric emptying, and enhance satiety, while concurrent glucagon receptor agonism elevates energy expenditure and promotes lipolysis. The hyperglycemic effect of glucagon receptor activation is counterbalanced by GLP-1 and GIP receptor-mediated insulinotropic activity, yielding a net anabolic-sparing, fat-oxidizing metabolic state.
weight loss
- Clinical trials show 17.5% weight loss at 24 weeks and 24.2% at 48 weeks.
- Continuous weight loss with no plateau at 48 weeks suggests greater long-term potential.
- Addresses obesity through appetite suppression, energy expenditure, and metabolic efficiency.
type 2 diabetes
- HbA1c reductions up to 2.16% with 82% achieving target levels below 6.5%.
- Balanced glycemic control with minimal hypoglycemia risk.
- Marked improvements in sensitivity with potential for reduced exogenous insulin requirements.
cardiovascularmetabolic
- Non-HDL cholesterol reductions up to 26.9%, triglyceride reductions up to 40.6%.
- Consistent decreases in systolic and diastolic blood pressure across trials.
- Up to 82% reduction in liver fat with normalization in 90% of participants.
Research Dose (Reference)
Starting 2mg weekly, escalating to 4–12mg weekly
Research Frequency (Reference)
once weekly
Research Cycle (Reference)
Titrated over 12 weeks to maintenance dose; studied up to 48–68 weeks
Storage
Lyophilized: -20°C or below, protected from light. Reconstituted: 2–8°C for up to 28 days; do not freeze reconstituted solution.
Chemical Makeup
Key benefits
Produces up to 24–29% total body weight reduction over 48–68 weeks, exceeding efficacy of existing single and dual incretin therapies
Reduces visceral and hepatic fat, with Phase 2a data showing significant improvements in liver steatosis in MASLD patients
Lowers HbA1c in a dose-dependent manner, improving glycemic control in patients with type 2 diabetes and obesity
Improves kidney function markers, with the 12mg dose reducing urinary albumin by up to 31.5% in Phase 2 participants
Community interest
This peptide is still gaining traction in the community.
Triple Receptor Agonist | Obesity & Metabolic Disease
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoGLP-3 Molecular Information
View the scientifc details of GLP-3.
40
Amino Acids
GLP-3
His
His
Position 1
Sec
Sec
Position 2
Glu
Glu
Position 3
Gly
Gly
Position 4
Thr
Thr
Position 5
Phe
Phe
Position 6
Thr
Thr
Position 7
Ser
Ser
Position 8
Asp
Asp
Position 9
Val
Val
Position 10
Ser
Ser
Position 11
Ser
Ser
Position 12
Tyr
Tyr
Position 13
Leu
Leu
Position 14
Glu
Glu
Position 15
Gly
Gly
Position 16
Gln
Gln
Position 17
Ala
Ala
Position 18
Ala
Ala
Position 19
Lys
Lys
Position 20
Glu
Glu
Position 21
Phe
Phe
Position 22
Ile
Ile
Position 23
Ala
Ala
Position 24
Trp
Trp
Position 25
Leu
Leu
Position 26
Val
Val
Position 27
Arg
Arg
Position 28
Gly
Gly
Position 29
Arg
Arg
Position 30
Gly
Gly
Position 31
Pro
Pro
Position 32
Ser
Ser
Position 33
Ser
Ser
Position 34
Gly
Gly
Position 35
Ala
Ala
Position 36
Pro
Pro
Position 37
Pro
Pro
Position 38
Pro
Pro
Position 39
Ser
Ser
Position 40
Molecular Weight
4731.33DaChain Length
40Amino AcidsType
PeptideGLP-3 Protocols
Subcutaneous injection is the only clinically documented route for GLP-3, administered once weekly in the abdomen, outer thigh, or upper arm. The protocol follows a gradual dose-escalation titration schedule starting at 1–2 mg per week to minimize GI side effects before reaching a maintenance dose of 4–12 mg weekly.
1000 mcg
Escalation
Establish GI tolerability before advancing to therapeutic dose
SubQ
1 week range
12000 mcg
High Maintenance
Maximize weight loss in patients who plateau at lower doses — up to 24% body weight reduction observed in Phase 2
SubQ
1 week range
4000 mcg
Low Maintenance
Sustain initial weight loss and appetite suppression at a well-tolerated dose
SubQ
1 week range
8000 mcg
Mid Maintenance
Achieve full therapeutic weight loss response in the primary efficacy range
SubQ
1 week range
4000 mcg
Glycemic Control
Reduce HbA1c and achieve euglycemia in Type 2 diabetes alongside weight reduction
SubQ
1 week range
12000 mcg
Cardiovascular Risk Reduction
Reduce cardiometabolic risk factors including visceral fat, triglycerides, and hepatic steatosis at maximum studied dose
SubQ
1 week range
GLP-3 Reconstitution Guide
Learn how to reconstitute GLP-3
Materials needed
Insulin syringes (0.5–1 mL, 29–31 gauge) for injection
3–5 mL syringe with 18–23 gauge needle for drawing BAC water
Bacteriostatic water (BAC water), 2 mL per 10 mg vial
Alcohol swabs
Retatrutide lyophilized powder vial (5 mg, 10 mg, 20 mg, or 30 mg)
Calculate your target concentration before reconstitution — a standard setup is 2 mL bacteriostatic water per 10 mg vial yielding 5 mg/mL
Wash hands thoroughly with soap and water for at least 20 seconds
Wipe the rubber stopper of both the peptide vial and BAC water vial with separate alcohol swabs and allow to dry for 10–15 seconds
Draw the required volume of bacteriostatic water into a 3–5 mL syringe using an 18–23 gauge needle
Insert the needle into the Retatrutide vial and slowly inject the BAC water down the inside glass wall of the vial over 10–20 seconds — never squirt directly onto the powder
Remove the syringe and gently swirl the vial in a circular motion until fully dissolved (1–3 minutes) — do not shake
Inspect the solution under light — it should be clear and colorless; discard if cloudy, discolored, or particulate matter is visible
Label the vial with the peptide name, concentration, reconstitution date, and 28-day expiry date
Refrigerate immediately at 2–8°C (36–46°F) and allow the vial to come to room temperature for 5–10 minutes before each injection
Draw the calculated dose volume into an insulin syringe, clean the injection site with an alcohol swab, pinch the skin, and inject at a 45–90° angle subcutaneously
Rotate injection sites each week between the abdomen (2+ inches from navel), outer thigh, and back of upper arm to prevent lipohypertrophy
GLP-3 Cycle
The GLP-3 Cycle section explains how long a typical cycle lasts and what research data suggests about each phase. In research contexts, biological systems may show reduced responsiveness with continuous exposure.
Research protocols often include washout periods between cycles to study baseline recovery and maintain experimental validity.
- Week 1-2
- Initial appetite suppression and mild GI effects as body adapts to triple hormone activation
- Week 2-4
- Noticeable food cravings reduction and portion size decrease; early weight loss (2-5%)
- Week 4-8
- Significant appetite control and steady weight loss (5-10%); improved glucose control
- Week 8-16
- Substantial weight reduction (10-18%) with enhanced energy expenditure
- Week 16-24
- Major weight loss milestone (15-22%) with cardiovascular benefits and liver fat reduction
- Week 24-48
- Maximum clinical efficacy (20-24.2%) with comprehensive metabolic improvements
Dosing tools
GLP-3 Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The research quantity per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
GLP-3
SINGLE COMPOUNDVolume per draw
0.05
mL
Concentration
10.00
mg/mL
Draws per vial
20
draws
Total draws per vial
20 draws
How it works
Based on a 10 mg GLP-3 vial diluted with 1 mL of bacteriostatic water, each 500 mcg research quantity equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Our top-rated vendor
Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing — no paid placements, no affiliate influence. We update this list as new data comes in.
Based on current scores, this vendor ranks highest across those criteria.
#1 Rated Research Peptide Supplier
Reference Guide
Dosing Cycle
- Peptide
- GLP-3
- Dosing
- Starting 2mg weekly, escalating to 4–12mg weekly
- Dosing Frequency
- once weekly
- Cycle Duration
- Titrated over 12 weeks to maintenance dose; studied up to 48–68 weeks
- Storage
- Lyophilized: -20°C or below, protected from light. Reconstituted: 2–8°C for up to 28 days; do not freeze reconstituted solution.
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC)contains 0.9% benzyl alcohol for preservation in research solutions
- Add liquid slowly during reconstitutionaim down the vial wall, not directly onto lyophilized powder
- Never shakegently swirl or roll the vial until fully dissolved
- Store properlyrefrigerate reconstituted solutions at 2–8°C
- Use within 28 daysmost reconstituted peptides remain stable for approximately 4 weeks
- Maintain sterilityclean vial septa with alcohol swabs before each draw
Peptide Interactions
Research suggestions of GLP-3 interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
Safe combination; BPC-157 may provide GI protective benefits during retatrutide use.
Weight
cag
Metabolic
Cagrilintide
MONITOR
Both cause significant GI effects. Not recommended without specialist supervision.
Weight
GLP-1
Metabolic
GLP-1
AVOID
Do not combine—overlapping GLP-1 agonist mechanisms increase severe hypoglycemia risk.
Weight
GLP-2
Metabolic
GLP-2
AVOID
Do not combine with other dual/triple agonists—risk of severe hypoglycemia and excessive GI effects.
Side effects
Avoid combining in research: Research combining GLP-3 with GLP-1, GLP-2.
Monitor in research: Exercise caution when studying GLP-3 with Cagrilintide.
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Stop signs
Severe persistent nausea or vomiting preventing adequate nutrition
Signs of pancreatitis: severe abdominal pain radiating to back
Severe hypoglycemia symptoms: confusion, dizziness, sweating
Excessive weight loss (>3 lbs per week consistently or >25% total body weight)
Gallbladder problems: severe right upper abdominal pain
Bad signs
GLP-3Research References
GLP-3 is a preclinical compound
GLP-3
GLP-3 is a preclinical compound
Phase II Obesity Trial
Landmark RCT in 338 participants showing dose-dependent weight loss; 12mg dose achieved 24.2% reduction—highest recorded for any obesity medication. NEJM.
2023
Phase II Type 2 Diabetes Study
Trial in 281 participants with type 2 diabetes: 16.9% weight loss and HbA1c reductions up to 2.16%. The Lancet.
2023
MASLD Substudy
Metabolic dysfunction-associated steatotic liver disease study: 82% liver fat reduction with normalization in >90% at highest doses. Nature Medicine.
2024
Structural Insights into Triple Agonism
Cryo-EM structures reveal simultaneous activation of GLP-1R, GIPR, and GCGR, explaining superior clinical efficacy. Cell Discovery.
2024
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringe units to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
Calculate peptide research quantities
Reference our peptide dosage, blend, and accumulation calculators for research purposes. Enter vial size, reconstitution volume, and target research quantity to calculate draw volumes instantly. For research use only — not administration or dosing guidance of any kind.
